Drug Trial Radar · NCT03722329
Pharmacokinetic, Safety, Tolerability, Immunogenicity, and Pharmacodynamic Study of SB12 in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Jan 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
240
Actual
Start
Nov 13, 2018
Primary completion
Mar 29, 2019
Study completion Apr 8, 2019
Sponsor
- Lead sponsor
- Samsung Bioepis Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 26, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is to evaluate PK, safety, tolerability, immunogenicity, and PD profiles of SB12, EU sourced Soliris, and US sourced Soliris in healthy subjects.
Conditions
- Healthy
Interventions
EculizumabDrug
Eculizumab Injection. 300 mg, single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUCinfTime frame: Day 1 to Day 64
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PAREXEL International GmbH, Early Phase Clinical Unit - Berlin
Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.